15 th annual retina fel lows’ forum · 2016-12-18 · early stage biopharmaceutical company that...

12
JANUARY -, Westin Chicago River North Chicago, IL Course Director: David R.Chow, MD Course Co-Directors: Carl C. Awh, MD; Tarek S. Hassan, MD Retina Fellows’ Forum 15 TH ANNUAL

Upload: others

Post on 03-Aug-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

JANUARY -, Westin Chicago River North

Chicago, IL

Course Director: David R.Chow, MD

Course Co-Directors: Carl C. Awh, MD; Tarek S. Hassan, MD

Retina Fellows’ Forum

15TH ANNUAL

� �

��

Page 2: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen
Page 3: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

Tarek S. Hassan, MDCourse Co-DirectorAssociated Retinal ConsultantsRoyal Oak, MI (248) [email protected]

Dean Eliott, MDMassachusetts Eye and Ear InfirmaryBoston, MA(617) [email protected]

David R. Chow, MD, FRCS(C)Course DirectorUniversity of TorontoToronto, ON Canada(416) [email protected]

Maria H. Berrocal, MDBerrocal & AssociatesSan Juan, PR(787) [email protected]

Carl C. Awh, MDCourse Co-DirectorTennessee RetinaNashville TN (615) [email protected]

Jonathan L. Prenner, MDRobert Wood Johnson Medical SchoolNew Brunswick, NJ (609) [email protected]

Tamer H. Mahmoud, MD, PhDDuke University Eye CenterDurham, NC(919) [email protected]

J. Michael Jumper, MDWest Coast Retina Medical GroupSan Francisco CA (415) [email protected]

Mark S. Blumenkranz, MD, MMSHJ Smead Professor and ChairmanDepartment of OphthalmologyDirector, Byers Eye Institute at StanfordPalo Alto, CA(650) [email protected]

Distinguished Guest Speaker

Faculty

Page 4: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

Mark S. Blumenkranz, MD is the HJSmead Professor and Chairman of theDepartment of Ophthalmology, andthe founding Director of the Byers EyeInstitute at Stanford University, a60,000 sq. foot state of the art medicaland research facility, whose design andconstruction he spearheaded and thatwas completed in 2010. He obtainedhis Baccalaureate, Master of MedicalScience in Biochemical Pharmacology,and MD degrees at Brown, a Residencyin Ophthalmology at Stanford, and aFellowship in Vitreo-Retinal diseases atthe Bascom Palmer Eye Institute of theUniversity of Miami. He completed theExecutive Program at the StanfordGraduate School of Business in 2004.

Dr. Blumenkranz is the author ofmore than 150 peer-reviewed publica-tions and book chapters, and multiplepatents in the area of vitreo-retinaldiseases, with special interests in ocularpharmacology, and new microsurgicaland laser-based devices and techniques.He has received numerous awards forhis many contributions including theJackson Award Lecture in 2013, andhas served on the Editorial Boards ofmany of the leading journals in thefield, including the American Journal of Ophthalmology, Ophthalmology,Graefe’s Archives for Ophthalmology,and Retina amongst others.

He is a past President of the MaculaSociety, the Retina Society and the

American University Professors ofOphthalmology. He is a Fellow of theCorporation of Brown University,where he serves as chairman of theMedical School Committee.

Dr Blumenkranz has a longstandinginterest and expertise in university-corporate technology transfer and earlystage biomedical company developmenthaving either founded or served on theBoards of Directors of a number ofsuccessful medical drug and devicecompanies. He has been a Director ofOIS, Midlabs and Oculex Pharma -ceuticals in the past. At Oculex he was also Chairman of the SAB and theprincipal designer of the successfulphase 2 Ozurdex trial, leading to itsacquisition by Allergan in 2003 for $230M.

He served as a Founder, Director andChairman of the SAB at Macusight, anearly stage biopharmaceutical companythat developed an ocular formulationfor Sirolimus, and which was acquiredby Santen in 2010. He was a Founderand Director of Peak Surgical, aninnovator in pulsed plasma mediatedelectro-surgery that was acquired byMedtronics in 2011 for $120M. In2004 he co-founded Optimedica Corp.for which he co-wrote the foundationIP for the PASCAL and Catalys lasers.Optimedica was acquired by AbbottMedical Optics in 2013 in a dealvalued at $400M including an upfront

cash payment of $250M and subse-quent milestone based payments of $150M.

Dr. Blumenkranz continues to beinvolved as a founder and director in anumber of active biopharmaceuticaland medical device companies. He iscurrently Chairman of the Board ofAvalanche Biotechnologies, an oculargene therapy company, which he co-founded and co-wrote the foundationIP for in 2006.

He is Chairman of the Board, a co-founder and foundation IP author ofDigisight Corporation, an ophthalmicm-health and cloud-based electronicmedical record platform focusing onout of office diagnostics. He is a directorand co-author of the foundation IP forVantage Surgical, an early stage surgicalimaging company. He is a founder, IPco-author and director of CombangioCorp., a pre-clinical stage biopharma-ceutical company developing proteinengineering based therapies for oculardisease.

He is also a director of two Irelanddomiciled companies. Presbia Corp. isthe developer of a novel proceduraltreatment employing an intra cornealpolymeric implant for age related lossof near vision, that is in FDA trials in the U.S. Optimyst Systems is apreclinical stage company developing a novel method for ophthalmic topicaldrug application.

Distinguished Guest SpeakerMARK S. BLUMENKRANZ, MD, MMS

Looking Back a Decade at the Pyron Lecture… and Finding Your Place in the Grand Scheme of Things... You Are the Author of Your Own Narrative

, • :

Page 5: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

FridayJan 23:-:

Registration/Welcome Reception

:-:

Exhibit Hall

:-:

Session 1

:-:

WelcomeDavid R. Chow, MD

:-:

AMDJonathan L. Prenner, MD

:-:

SPONSOR PRESENTATIONSAllergan, Inc.

Volk Optical, Inc.

Topcon Medical Laser Systems, Inc.

Optos, Inc.

:-:

Ancillary Diagnostic TestingDavid R. Chow, MD

:-:

Nutritional Supplementation and Genetic Testing for ARMDCarl C. Awh, MD

:-:

Break

:-:

Session 2

:-:

SPONSOR PRESENTATIONSIridex Corp.

Carl Zeiss Meditec, Inc.

Insight Instruments, Inc.

Keeler Instruments, Inc.

:-:

Retinal Detachment ManagementJ. Michael Jumper MD

:-:

Management of Subretinal HemorrhageTamer H. Mahmoud MD, PhD

:-:

SPONSOR PRESENTATIONSQuantel Medical, Inc.

OCULUS Surgical, Inc.

Alimera Sciences, Inc.

:-:

Welcome Dinner

Page 6: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

SaturdayJan 24:-:

Breakfast

: -:

Exhibit Hall

:-:

Session 3

:-:

Retinal Trivial Pursuit

:-:

Diabetic Macular EdemaTarek S. Hassan, MD

:-:

Vitrectomy for Diabetic RetinopathyMaria H. Berrocal, MD

:-:

SPONSOR PRESENTATIONSAlcon Laboratories, Inc.

Dutch Ophthalmic, USA

Synergetics, Inc.

:-:

Break

:-:

Session 4

:-:

Faculty Pearls in Medical Retina

The Most Common Unusual Medical Retina ConditionsDean Eliott, MD

OcriplasminDavid R. Chow MD

:-:

Retinal Vein OcclusionTarek S. Hassan, MD

:-:

TraumaDean Eliott, MD

:-:

Break

:-:

Session 5

:-:

Macular SurgeryJ. Michael Jumper, MD

:-:

MAJOR SPONSOR PRESENTATION

:-:

Looking Back a Decade at the PyronLecture… and Finding Your Place in the Grand Scheme of Things... You are the Author of Your Own NarrativeMark S. Blumenkranz, MD, MMSDistinguished Guest Speaker

Page 7: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

:-:

Lunch

:-:

SPONSOR PRESENTATIONRegeneron Pharmaceuticals, Inc.

:-:

Session 6

:-:

SPONSOR PRESENTATIONSBausch + Lomb

MedOne Surgical, Inc.

ThromboGenics, Inc.

:-:

Announcements

:-:

Vitreoretinal Surgery 101David R. Chow, MD

:-:

Break

:-:

Relocate to Astor Ballroom

:-:

Session 7

:-:

Faculty Surgical Pearls

Pearls in EndophthalmitisDean Eliott, MD

Retained Lens FragmentsMaria H. Berrocal, MD

Dislocated IOLsJonathan L. Prenner, MD

:-:

Starting Your Career – The Real WorldCarl C. Awh, MD

:-:

Wrap-up

:

Distribution of Reimbursements

:

Depart for 10Pin Bowling Lounge from Hotel Lobby

:-:

Dinner and Awards at 10Pin10th Annual Fellows’ Forum Bowling Tournament

SundayJan 25:-:

Breakfast (served in Lobby)

Page 8: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

Ashkan Abbey, MDAssociated Retinal Consultants/William Beaumont [email protected]

Marwan Abdulaal, MD, PhDBeetham Eye Institute/Joslin Diabetes [email protected]

Shawn Agee, MDRetina Consultants of [email protected]

Khushboo Agrawal, MDNew York Eye and Ear [email protected]

David Almeida, MD, MBA, PhDUniversity of [email protected]

Hossein Ameri, MD, PhDUniversity of Southern California Eye [email protected]

Simon Bababeygy, MDUniversity of California, [email protected]

Robert Beardsley, MDUniversity of [email protected]

Nicole Beharry, MDRetina Specialists of [email protected]

Thomas Berenberg, MDWeill Cornell Medical [email protected]

Eric Brinton, MDUniversity of [email protected]

Cindy Calderon, MDVitreoretinal Foundation [email protected]

Joshua N. Carlson, MDVanderbilt Medical [email protected]

Khurram Chaudhary, MDUniversity of [email protected]

Eric Chin, MDUniversity of [email protected]

David Chin Yee, MDWashington [email protected]

Steven R. Cohen, MDUniversity of [email protected]

Victor Copeland, MDWake Forest [email protected]

Wayne Davis, DOUniversity of [email protected]

Matthew Debiec, MDEmory Eye [email protected]

Sheila Garcia Santana, MDYale [email protected]

Mohamed Gendy, MDMedical College of [email protected]

Iuri Golubev, MDLSU/New [email protected]

Mrinali Patel Gupta, MDWeill Cornell Medical [email protected]

Justin Gutman, MDUT [email protected]

Shamim Haji, MDUniversity of Florida, [email protected]

Ian Han, MDWilmer Eye [email protected]

Samuel K.“Steve” Houston, MDWills Eye [email protected]

Cindy Hwang, MDEmory Eye [email protected]

Sujit Itty, MDJules Stein Eye Institute/[email protected]

Loren Jack, MDUniversity of Nebraska Medical [email protected]

Jesse Jung, MDColumbia [email protected]

Peter A. Karth, MD, MBAStanford [email protected]

Ajay E. Kuriyan, MDBascom Palmer Eye [email protected]

David Lally, MDNew England Eye Center Tufts University School of [email protected]

Brian Lehpamer, MDBaylor College of [email protected]

Ashleigh Levison, MDCole Eye Institute/Cleveland [email protected]

Shawn Lewis, MDUniversity of [email protected]

Michelle Liang, MDTufts/Ophthalmic Consultants of [email protected]

Participating Fellows

Page 9: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

Enchun “Mike” Liu, MDRetina Institute St. [email protected]

Joshua Mali, MDAlbany Medical [email protected]

Michael McClintock, MDIllinois Retina Associates/Rush [email protected]

John B. Miller, MDMassachusetts Eye and Ear [email protected]

Bobeck Modjtahedi, MDMassachusetts Eye and Ear [email protected]

Amir Mohsenin, MD, PhDBascom Palmer Eye [email protected]

Mikelson MomPremier, MDValley Retina [email protected]

Arash Mozayan, MDShiley Eye Center, UC San [email protected]

Joseph Nezgoda, MDShiley Eye Center, UC San [email protected]

Kristen Nwanyanwu, MD, MBAUniversity of Illinois at [email protected]

Ahmet Ozkok, MDUniversity of [email protected]

Camille Palma, MDNorthwestern [email protected]

Jonathan Park, FRCOphthUniversity of [email protected]

Eustace Penniecook, MDValley Retina [email protected]

Kyle Piwonka, DOValley Retina [email protected]

Cynthia X. Qian, MDMassachusetts Eye and Ear [email protected]

Ehsan Rahimy, MDWills Eye [email protected]

Jessica Randolph, MDRetina and Vitreous of [email protected]

David Reed, MDWills Eye [email protected]

Damien Rodger, MD, PhDUniversity of Southern California Eye [email protected]

Kevin Rosenberg, MDKresge Eye [email protected]

Archana Thangappan Seethala, MDBoston University/Boston Medical [email protected]

Raza Shah, MDAssociated Retina Consultants of [email protected]

Ankoor Shah, MDAssociated Retinal Consultants/William Beaumont [email protected]

Sumit Sharma, MDDuke University Eye [email protected]

Frank S. Siringo, MD, ODUniversity of [email protected]

Adiel Smith, MDCole Eye Institute/Cleveland [email protected]

Sandra J. Sofinski, MDSouth Texas Retina [email protected]

Jennifer Spiegel, MDOchnser Medical [email protected]

Danielle Strauss, MDNew York Eye and Ear [email protected]

William Terrell, MDThe Ohio State [email protected]

Nicholas Tosi, MD, MBAUniversity of Alabama at [email protected]

Brian Toussaint, MDCincinnati Eye [email protected]

Harpreet Walia, MDRetina Institute St. [email protected]

Tyson Ward, MDUniversity of [email protected]

Daniel Warder, MD, FRCSCUniversity of [email protected]

Ryan Wong, MDJules Stein Eye Institute/[email protected]

Page 10: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

ALCON LABORATORIES, INC.

Andrew BerkowitzNational Surgical [email protected]

Michael LeeUS Marketing [email protected]

ALIMERA SCIENCES

Kevin CadyMidwest Sales [email protected]

Eileen [email protected]

ALLERGAN, INC.

Harry DavisNational Sales Director [email protected]

Rachel RenshawProf. Relations & Strat [email protected]

BAUSCH + LOMB

Paul GliebeSr. Vitreoretinal [email protected]

Christian HabinaRegional Area [email protected]

Scott HamorDirector, [email protected]

David MyersProduct Manager [email protected]

Roeland PapenMarketing [email protected]

Rich ShimoloensSr. Vitreoretinal Sales [email protected]

CARL ZEISS MEDITEC, INC.

Kevin LangtonStrategic Business [email protected]

DUTCH OPHTHALMIC, USA

Kim Irwin-PackMarketing [email protected]

Vic WildenradtTerritory Mgr, Upper [email protected]

GENENTECH, INC.

Caroline HartfordSr. Product [email protected]

Krissy KlimekClinical [email protected]

Deric LittrellClinical [email protected]

Mila [email protected]

Jamey [email protected]

Peggy [email protected]

INSIGHT INSTRUMENTS, INC.

Will CarpenterSr. Surgical Sales [email protected]

Emily GomezInside Sales [email protected]

IRIDEX CORP.

Joan StaufferProduct Marketing [email protected]

Ralph PrchalArea Sales [email protected]

KEELER INSTRUMENTS, INC.

Martin HenrySales [email protected]

MEDONE SURGICAL, INC.

Bruce [email protected]

Corporate Representatives

Page 11: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

OCULUS SURGICAL, INC.

David BedoreSurgical Sales [email protected]

John DiscenzaSurgical Sales [email protected]

OPTOS, INC.

Jeff McClimansAccount [email protected]

QUANTEL MEDICAL, INC.

Shauna StaceyRegional Sales [email protected]

REGENERONPHARMACEUTICALS, INC.

Abby CahnSr. Mgr. Strategic Accounts [email protected]

Jordy WetzelAssoc. Dir. [email protected]

SYNERGETICS, INC.

Bob NeuSr. Product [email protected]

Beth BrauerTerritory [email protected]

THROMBOGENICS, INC.

Bryan BischelManager, Medical [email protected]

Beau KesslerSr. Manager, Strategic [email protected]

TOPCON MEDICAL LASER SYSTEMS, INC.

Ricardo AlmironSr. Product [email protected]

VOLK OPTICAL INC.

Jake IselinMarketing [email protected]

Pete [email protected]

Page 12: 15 TH ANNUAL Retina Fel lows’ Forum · 2016-12-18 · early stage biopharmaceutical company that developed an ocular formulation for Sirolimus, and which was acquired by Santen

Special Thanks On behalf of the faculty and participants of the

15th Annual Retina Fellows’ Forum, we thank our

MAJOR CORPORATE SPONSOR

whose generous support made this meeting possible.

We also gratefully acknowledge the following companies for their contributions:

BRONZEBausch + Lomb

Regeneron Pharmaceuticals, Inc.

SILVERAlcon Laboratories, Inc.

Alimera SciencesAllergan, Inc.

Carl Zeiss Meditec, Inc.Dutch Ophthalmic, USAInsight Instruments Inc.

Iridex Corp. Keeler Instruments Inc.MedOne Surgical, Inc.

OCULUS Surgical Optos Inc.

Quantel Medical Inc. Synergetics, Inc.

ThromboGenics Inc.Topcon Medical Laser Systems, Inc.

Volk Optical, Inc.

EDUCATIONAL GRANTSThis meeting is also supported by educational grants from

Bausch + LombRegeneron Pharmaceuticals, Inc.

MEDICAL CONFERENCE PLANNERS, INC.

[email protected]

www.medconfs.com